Маркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ
dc.citation.epage | 125 | |
dc.citation.issue | 1 | |
dc.citation.spage | 116 | |
dc.contributor.affiliation | Національний університет “Львівська політехніка” | |
dc.contributor.affiliation | Lviv Polytechnic National University | |
dc.contributor.author | Стасевич, М. В. | |
dc.contributor.author | Зварич, В. І. | |
dc.contributor.author | Stasevych, M. V. | |
dc.contributor.author | Zvarych, V. I. | |
dc.coverage.placename | Львів | |
dc.coverage.placename | Lviv | |
dc.date.accessioned | 2024-01-22T08:14:43Z | |
dc.date.available | 2024-01-22T08:14:43Z | |
dc.date.created | 2021-03-16 | |
dc.date.issued | 2021-03-16 | |
dc.description.abstract | Проведено маркетинговий аналіз фармацевтичного ринку лікарських засобів – похідних 9,10-антрахінону. Показано, що на ринку України асортимент цих препаратів сформований переважно лікарськими засобами закордонного виробництва, лідерами якого є країнивиробники Австрія, Італія, Німеччина та Індія. Визначено, що більшість антрахінонвмісних лікарських препаратів представлена засобами для лікування онкологічних захворювань різних типів та посилення перистальтики кишечника. Встановлено, що в Україні виробництвом трьох протипухлинних субстанцій займається ТОВ “Сінбіас Фарма”. Вітчизняними виробниками препаратів на основі антрахінонвмісної лікарської рослинної сировини є ПрАТ “Ліктрави” та ПрАТ Фармацевтична фабрика “Віола”, а виробниками глікозидів сени – АТ “Лубнифарм”, ТОВ “Тернофарм” та Фармацевтична компанія “Здоров’я”. Основними лікарськими формами лікарських засобів – похідних 9,10-антрахінону є ін’єкційні розчини, ліофілізати, таблетки та капсули тверді. | |
dc.description.abstract | A marketing analysis of the pharmaceutical market for drugs - derivatives of 9,10-anthraquinone was carried out. It is shown that in the Ukrainian market, the vast majority of the assortment of these drugs is formed by foreign-made drugs, the leaders of which are the manufacturing countries Austria, Italy, Germany and India. It has been determi ned that the majority of anthraquinone drugs are represented by agents for the treatment of diseases of varioustypes of cancer and strengthening ofthe intestinal reticulum.It has been established that “Sinbias Pharma” LLC is engaged in the production of four anticancer substances in Ukraine. For preparations based on anthraquinone-containing medicinal herbal raw materials, domestic manufacturers are PJSC “Liktravy” and PJSC Pharmaceutical Factory “Viola”, and the producers of senna glycosides are JSC “Lubnypharm”, “Ternopharm” LLC and Pharmaceutical company “Zdorovye”. Injection solutions, lyophilisates, tablets and hard capsules are the main dosage forms of drugs – derivatives of 9,10-anthraquinone. | |
dc.format.extent | 116-125 | |
dc.format.pages | 10 | |
dc.identifier.citation | Стасевич М. В. Маркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ / М. В. Стасевич, В. І. Зварич // Chemistry, Technology and Application of Substances. — Львів : Видавництво Львівської політехніки, 2021. — Том 4. — № 1. — С. 116–125. | |
dc.identifier.citationen | Stasevych M. V. Marketing analysis of the market segment of drugs – derivatives of 9,10-anthraquinone in Ukraine / M. V. Stasevych, V. I. Zvarych // Chemistry, Technology and Application of Substances. — Lviv : Lviv Politechnic Publishing House, 2021. — Vol 4. — No 1. — P. 116–125. | |
dc.identifier.doi | doi.org/10.23939/ctas2021.01.116 | |
dc.identifier.uri | https://ena.lpnu.ua/handle/ntb/60846 | |
dc.language.iso | uk | |
dc.publisher | Видавництво Львівської політехніки | |
dc.publisher | Lviv Politechnic Publishing House | |
dc.relation.ispartof | Chemistry, Technology and Application of Substances, 1 (4), 2021 | |
dc.relation.references | 1. Fouillaud, M., Venkatachalam, M., GirardValenciennes, E., Caro, Y., Dufossé, L.(2016). Anthraquinones and derivatives from marine-derived fungi: Structural Diversity and Selected Biological Activities. Marine Drugs, 14(4), 64. doi:10.3390/md14040064. Retrieved from https://www.mdpi.com/1660-3397/14/4/64 | |
dc.relation.references | 2. Fouillaud, M., Caro, Y., Venkatachalam, M., Grondin, I., & Dufossé L. (2018). Anthraquinones. In: L. M. L. Nollet; J. A. Gutiérrez-Uribe (eds). Phenolic Compounds in Food Characterization and Analysis, 130–170. CRC Press. | |
dc.relation.references | 3. Malik, E. M. & Müller, C. E. (2016). Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews, 36, 705–748. doi:10.1002/med.21391 | |
dc.relation.references | 4. Hussain, H., Al-Harrasi, A., Al-Rawahi, A., Green, I. R., Csuk, R., Ahmed, I., Shah, A., Abbas, G., Rehman, N. U. & Ullah, R. (2015). A fruitful decade from 2005 to 2014 for anthraquinone patents, Expert Opinion on Therapeutic Patents, 25(9), 1053–1064. doi:10.1517/13543776.2015.1050793 | |
dc.relation.references | 5. Tikhomirov, A. S., Shtil, A. A., Shchekotikhin, A. E. (2018). Advances in the Discovery of Anthraquinone-Based Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 159–183. doi:10.2174/1574892813666171206123114. | |
dc.relation.references | 6. Siddamurthi, S., Gutti, G., Jana, S., Kumar, A., & Singh S. K. (2020). Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Medicinal Chemistry, 12(11), 1037–1069. doi:10.4155/fmc-2019-0198. | |
dc.relation.references | 7. Zvarich, V. I., Stasevich, M. V.; Stan’ko, O. V.; Komarovskaya-Porokhnyavets, E. Z.; Poroikov, V. V.; Rudik, A. V.; Lagunin, A. A.; Vovk, M. V.; & Novikov, V. P. (2014). Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharmaceutical Chemistry Journal, 48, 584–588. doi: 10.1007/s11094-014-1154-z. | |
dc.relation.references | 8. Zvarych, V., Stasevych, M., Novikov, V., & Vovk, M. (2021). Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthraceny l)Acetamides, Biointerface Research in Applied Chemistry, 11(1), 7725–7734. doi: 10.33263/BRIAC111.77257734 | |
dc.relation.references | 9. Zvarych, V., Stasevych, M., Novikov, V., Rusanov, E., Vovk, M., Szweda, P., Grecka, K., & Milewski, S. (2019). Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules, 24, 4581. doi:10.3390/molecules24244581. Retrieved from https://www.mdpi.com/1420-3049/24/24/4581 | |
dc.relation.references | 10. Halenova, T.I., Nikolaeva,I. V., Stasevych,M. V., Zvarych, V. I., Lunin, V. V., Novikov, V. P., & Savchuk, O. M. (2017). Platelet aggregation under the influence of some dithiocarbamate derivatives of 9,10-anthracenedione. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8, 1626–1632. Retrieved from https://www.rjpbcs.com/pdf/2017_8(1)/[203].pdf | |
dc.relation.references | 11. Stasevych, M. V., Zvarych, V. I., Spreis, D. R., & Yaremkevych, O. S. (2019). Computer prediction and verification of antioxidative activity of exo-functionalized derivatives of 9,10-antraquinone. Chemistry, Technology and Application of Substances, 2(1), 83–91. doi:10.23939/ctas2019.01.083 | |
dc.relation.references | 12. Thomson Reuters Integrity database. Retrieved from http:// https://integrity.clarivate.com/integrity/xmlxsl/ (accessed December 14, 2019) | |
dc.relation.references | 13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy, (2020). Retrieved from http://www.drlz.com.ua (in Ukrainian) | |
dc.relation.references | 14. A searchable version of the complete ATC index with DDDs “ATC/DDD Index 2021”. (2021). Retrieved from https://www.whocc.no/atc_ddd_index/ | |
dc.relation.references | 15. Spetsializovane medychne internet-vydannia dlia likariv, provizoriv, farmatsevtiv, studentiv medychnykh i farmatsevtychnykh vuziv “Kompendium Online”, (2021). Retrieved from https://compendium.com.ua (in Ukrainian) | |
dc.relation.references | 16. Servis “Liki control” (2021). Retrieved from http://likicontrol.com.ua. [in Ukrainian] | |
dc.relation.references | 17. Online database “DrugBank Online” (2021). Retrieved from https://www.drugbank.com | |
dc.relation.references | 18. Online database “Drugs.com” (2021). Retrieved from https://www.drugs.com | |
dc.relation.references | 19. Halterman, P., Vogelzang, N.J., Farabishahadel, A., & Goodman O.B. (2010). Mitoxantrone. In: Figg W., Chau C., Small E. (eds) Drug Management of Prostate Cancer. New York: Springer. | |
dc.relation.references | 20. Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E.,. Reginster, J. Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & aging, 33(2), 75–85. doi: 10.1007/s40266-016-0347-4 | |
dc.relation.references | 21. Report on Carcinogens, Fourteenth Edition (2016, November 3). Danthron. Retrieved from https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf | |
dc.relation.references | 22. Lichtman M. A. (2013). A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells, Molecules and Diseases, 50(2), 119–130. doi:10.1016/j.bcmd.2012.10.005 | |
dc.relation.references | 23. Manufacturing Issues Remain for Indevus’ Valstar (2008, January 11). Retrieved from https://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar Diaz-Muñoz, G., Miranda, I. L., Sartori, S. K., de Rezende, D. C., & Diaz, M. A. N. (2018). Chapter 11 – Anthraquinones: An Overview. Studies in Natural Products Chemistry, 58, 313–338. doi:10.1016/B978-0-444-64056-7.00011-8 | |
dc.relation.references | 24. Koval’ov, V. M., Pavlin, O. I., & Isakova, T. I. (2004). Farmakohnoziya z osnovamy biokhimiyi roslyn. Vyd-vo NFaU MTK-knyha, Kharkiv. | |
dc.relation.references | 25. Sait „Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny” (2021). Baytach. Retrieved from https://mozdocs.kiev.ua/likiview.php?id=28047 | |
dc.relation.references | 26. Sait „Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny” (2021). PYRALVEX Retrieved from https://mozdocs.kiev.ua/likiview.php?id=3333 | |
dc.relation.referencesen | 1. Fouillaud, M., Venkatachalam, M., GirardValenciennes, E., Caro, Y., Dufossé, L.(2016). Anthraquinones and derivatives from marine-derived fungi: Structural Diversity and Selected Biological Activities. Marine Drugs, 14(4), 64. doi:10.3390/md14040064. Retrieved from https://www.mdpi.com/1660-3397/14/4/64 | |
dc.relation.referencesen | 2. Fouillaud, M., Caro, Y., Venkatachalam, M., Grondin, I., & Dufossé L. (2018). Anthraquinones. In: L. M. L. Nollet; J. A. Gutiérrez-Uribe (eds). Phenolic Compounds in Food Characterization and Analysis, 130–170. CRC Press. | |
dc.relation.referencesen | 3. Malik, E. M. & Müller, C. E. (2016). Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews, 36, 705–748. doi:10.1002/med.21391 | |
dc.relation.referencesen | 4. Hussain, H., Al-Harrasi, A., Al-Rawahi, A., Green, I. R., Csuk, R., Ahmed, I., Shah, A., Abbas, G., Rehman, N. U. & Ullah, R. (2015). A fruitful decade from 2005 to 2014 for anthraquinone patents, Expert Opinion on Therapeutic Patents, 25(9), 1053–1064. doi:10.1517/13543776.2015.1050793 | |
dc.relation.referencesen | 5. Tikhomirov, A. S., Shtil, A. A., Shchekotikhin, A. E. (2018). Advances in the Discovery of Anthraquinone-Based Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 159–183. doi:10.2174/1574892813666171206123114. | |
dc.relation.referencesen | 6. Siddamurthi, S., Gutti, G., Jana, S., Kumar, A., & Singh S. K. (2020). Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Medicinal Chemistry, 12(11), 1037–1069. doi:10.4155/fmc-2019-0198. | |
dc.relation.referencesen | 7. Zvarich, V. I., Stasevich, M. V.; Stan’ko, O. V.; Komarovskaya-Porokhnyavets, E. Z.; Poroikov, V. V.; Rudik, A. V.; Lagunin, A. A.; Vovk, M. V.; & Novikov, V. P. (2014). Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharmaceutical Chemistry Journal, 48, 584–588. doi: 10.1007/s11094-014-1154-z. | |
dc.relation.referencesen | 8. Zvarych, V., Stasevych, M., Novikov, V., & Vovk, M. (2021). Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthraceny l)Acetamides, Biointerface Research in Applied Chemistry, 11(1), 7725–7734. doi: 10.33263/BRIAC111.77257734 | |
dc.relation.referencesen | 9. Zvarych, V., Stasevych, M., Novikov, V., Rusanov, E., Vovk, M., Szweda, P., Grecka, K., & Milewski, S. (2019). Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules, 24, 4581. doi:10.3390/molecules24244581. Retrieved from https://www.mdpi.com/1420-3049/24/24/4581 | |
dc.relation.referencesen | 10. Halenova, T.I., Nikolaeva,I. V., Stasevych,M. V., Zvarych, V. I., Lunin, V. V., Novikov, V. P., & Savchuk, O. M. (2017). Platelet aggregation under the influence of some dithiocarbamate derivatives of 9,10-anthracenedione. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8, 1626–1632. Retrieved from https://www.rjpbcs.com/pdf/2017_8(1)/[203].pdf | |
dc.relation.referencesen | 11. Stasevych, M. V., Zvarych, V. I., Spreis, D. R., & Yaremkevych, O. S. (2019). Computer prediction and verification of antioxidative activity of exo-functionalized derivatives of 9,10-antraquinone. Chemistry, Technology and Application of Substances, 2(1), 83–91. doi:10.23939/ctas2019.01.083 | |
dc.relation.referencesen | 12. Thomson Reuters Integrity database. Retrieved from http:// https://integrity.clarivate.com/integrity/xmlxsl/ (accessed December 14, 2019) | |
dc.relation.referencesen | 13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy, (2020). Retrieved from http://www.drlz.com.ua (in Ukrainian) | |
dc.relation.referencesen | 14. A searchable version of the complete ATC index with DDDs "ATC/DDD Index 2021". (2021). Retrieved from https://www.whocc.no/atc_ddd_index/ | |
dc.relation.referencesen | 15. Spetsializovane medychne internet-vydannia dlia likariv, provizoriv, farmatsevtiv, studentiv medychnykh i farmatsevtychnykh vuziv "Kompendium Online", (2021). Retrieved from https://compendium.com.ua (in Ukrainian) | |
dc.relation.referencesen | 16. Servis "Liki control" (2021). Retrieved from http://likicontrol.com.ua. [in Ukrainian] | |
dc.relation.referencesen | 17. Online database "DrugBank Online" (2021). Retrieved from https://www.drugbank.com | |
dc.relation.referencesen | 18. Online database "Drugs.com" (2021). Retrieved from https://www.drugs.com | |
dc.relation.referencesen | 19. Halterman, P., Vogelzang, N.J., Farabishahadel, A., & Goodman O.B. (2010). Mitoxantrone. In: Figg W., Chau C., Small E. (eds) Drug Management of Prostate Cancer. New York: Springer. | |
dc.relation.referencesen | 20. Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E.,. Reginster, J. Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & aging, 33(2), 75–85. doi: 10.1007/s40266-016-0347-4 | |
dc.relation.referencesen | 21. Report on Carcinogens, Fourteenth Edition (2016, November 3). Danthron. Retrieved from https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf | |
dc.relation.referencesen | 22. Lichtman M. A. (2013). A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells, Molecules and Diseases, 50(2), 119–130. doi:10.1016/j.bcmd.2012.10.005 | |
dc.relation.referencesen | 23. Manufacturing Issues Remain for Indevus’ Valstar (2008, January 11). Retrieved from https://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar Diaz-Muñoz, G., Miranda, I. L., Sartori, S. K., de Rezende, D. C., & Diaz, M. A. N. (2018). Chapter 11 – Anthraquinones: An Overview. Studies in Natural Products Chemistry, 58, 313–338. doi:10.1016/B978-0-444-64056-7.00011-8 | |
dc.relation.referencesen | 24. Koval’ov, V. M., Pavlin, O. I., & Isakova, T. I. (2004). Farmakohnoziya z osnovamy biokhimiyi roslyn. Vyd-vo NFaU MTK-knyha, Kharkiv. | |
dc.relation.referencesen | 25. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). Baytach. Retrieved from https://mozdocs.kiev.ua/likiview.php?id=28047 | |
dc.relation.referencesen | 26. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). PYRALVEX Retrieved from https://mozdocs.kiev.ua/likiview.php?id=3333 | |
dc.relation.uri | https://www.mdpi.com/1660-3397/14/4/64 | |
dc.relation.uri | https://www.mdpi.com/1420-3049/24/24/4581 | |
dc.relation.uri | https://www.rjpbcs.com/pdf/2017_8(1)/ | |
dc.relation.uri | https://integrity.clarivate.com/integrity/xmlxsl/ | |
dc.relation.uri | http://www.drlz.com.ua | |
dc.relation.uri | https://www.whocc.no/atc_ddd_index/ | |
dc.relation.uri | https://compendium.com.ua | |
dc.relation.uri | http://likicontrol.com.ua | |
dc.relation.uri | https://www.drugbank.com | |
dc.relation.uri | https://www.drugs.com | |
dc.relation.uri | https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf | |
dc.relation.uri | https://www.fdanews.com/articles/103010-manufacturing-issues-remain-forindevus-valstar | |
dc.relation.uri | https://mozdocs.kiev.ua/likiview.php?id=28047 | |
dc.relation.uri | https://mozdocs.kiev.ua/likiview.php?id=3333 | |
dc.rights.holder | © Національний університет “Львівська політехніка”, 2021 | |
dc.subject | 9 | |
dc.subject | 10-антрахінон | |
dc.subject | активний фармацевтичний інгредієнт | |
dc.subject | лікарський препарат | |
dc.subject | аналіз ринку лікарських препаратів на основі похідних 9 | |
dc.subject | 10-антрахінону | |
dc.subject | асортимент лікарських засобів | |
dc.subject | лікарська форма | |
dc.subject | лікарська рослинна сировина | |
dc.subject | гомеопатичні препарати | |
dc.subject | : 9 | |
dc.subject | 10-anthraquinone | |
dc.subject | active pharmaceutical ingredient | |
dc.subject | medicinal product | |
dc.subject | market analysis of drugs based on derivatives of 9 | |
dc.subject | 10-anthraquinone | |
dc.subject | range of drugs | |
dc.subject | dosage form | |
dc.subject | herbal raw materials | |
dc.subject | homeopathic preparations | |
dc.title | Маркетинговий аналіз сегмента ринку лікарських засобів – похідних 9,10-антрахінону в УкраїнІ | |
dc.title.alternative | Marketing analysis of the market segment of drugs – derivatives of 9,10-anthraquinone in Ukraine | |
dc.type | Article |
Files
License bundle
1 - 1 of 1